Pembrolizumab biosimilar - Biocad
Alternative Names: BCD-201Latest Information Update: 28 Mar 2024
At a glance
- Originator Biocad
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma
- Phase I Solid tumours
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Russia (IV, Infusion)
- 18 Jul 2022 Phase-III clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy) in Russia (IV) (NCT05986331)
- 08 Feb 2021 Phase-I clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Russia (IV) (NCT05739006)